NCT00412581View on ClinicalTrials.gov

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Melanoma

Interventions

DRUG

Lenalidomide

25 mg by mouth daily for 2 weeks, followed by 1 week of rest.

DRUG

Dacarbazine

600 mg/m\^2 intravenously on Day 1 of every study cycle.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER